Evidence map›Paper›PMID 20631143›Full record

ArticleJournal of virology2010

Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus.

Rebecca L R Powell, Thompson Kinge, Phillipe N Nyambi

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Rebecca L R PowellDepartment of Microbiology, New York University School of Medicine, New York, NY 10010, USA.
Thompson Kinge
Phillipe N Nyambi
Ministry of Public Health · CMNew York University · USVA NY Harbor Healthcare System · US

Funding

VIROLOGY COREP30AI027742 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DUSTIN, MICHAEL LORAN · 1989 to 2010
$19.4M
TRAINING PROGRAM IN TB AND HIV PREVENTION AND TREATMENTD43TW001409 · FIC · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LAAL, SUMAN · 2000 to 2011
$4.6M
Viral Evolution and Humoral Immune Response to Dual HIV-1 InfectionR01AI083142 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GORNY, MIROSLAW K · 2010 to 2015
$2.6M
EVOLUTION AND PROPERTIES OF HIV/SIV STRAINS IN CAMEROONR01AI047053 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NYAMBI, PHILLIPE N · 2000 to 2003
$2.6M
FIC NIH HHS D43 TW001409FIC NIH HHS TW01409NIAID NIH HHS AI027742-17NIAID NIH HHS AI47053NIAID NIH HHS P30 AI027742NIAID NIH HHS R01 AI047053NIAID NIH HHS R01 AI083142
6 · The paper itself

Abstract

High-risk cohorts in East Africa and the United States show rates of dual HIV-1 infection--the concomitant or sequential infection by two HIV-1 strains--of 50% to 100% of those of primary infection, and our normal-risk HIV-positive cohort in Cameroon exhibits a rate of dual infection of 11% per year, signifying that these infections are not exceptional. Little is known regarding the effect of dual infections on host immunity, despite the fact that they provide unique opportunities to investigate how the immune response is affected when challenged with diverse HIV-1 antigens. Using heterologous primary isolates, we have shown here that dual HIV-1 infection by genetically distant strains correlates with significantly increased potency and breadth of the anti-HIV-1 neutralizing antibody response. When the neutralization capacities of sequential plasma obtained before and after the dual infection of 4 subjects were compared to those of matched plasma obtained from 23 singly infected control subjects, a significant increase in the neutralization capacity of the sequential sample was found for 16/28 dually infected plasma/virus pairs, while only 4/159 such combinations for the control subjects exhibited a significant increase (P < 0.0001). Similarly, there was a significant increase in the plasma dilution capable of neutralizing 50% of virus (IC(50)) for 18/24 dually infected plasma/virus pairs, while 0/36 controls exhibited such an increase (P < 0.0001). These results demonstrate that dual HIV-1 infection broadens and strengthens the anti-HIV-1 immune response, suggesting that vaccination schemes that include polyvalent, genetically divergent immunogens may generate highly protective immunity against any HIV-1 challenge strain.

Indexed as

AfricaAntibodies, NeutralizingCameroonHIV-1HIV AntibodiesHIV InfectionsHumansInhibitory Concentration 50Neutralization TestsUnited StatesAntibodies, NeutralizingHIV Antibodies

Identifiers

PMID20631143
PMCPMC2937625
OpenAlexW2040949532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.